Revium Rx Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
David Akunis
Chief executive officer
US$223.2k
Total compensation
| CEO salary percentage | 4.0% |
| CEO tenure | less than a year |
| CEO ownership | n/a |
| Management average tenure | 1.8yrs |
| Board average tenure | 4.1yrs |
Recent management updates
No updates
Recent updates
CEO
David Akunis (58 yo)
less than a year
Tenure
US$223,200
Compensation
Mr. David Akunis is Chief Executive Officer of Revium Rx from December 23, 2024. He has 30 years’ experiences as senior corporate executive with an extensive knowledge in company development and venture ca...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chief Executive Officer | less than a year | US$223.20k | no data | |
| President | 5.3yrs | US$5.01m | 4.61% $ 1.4m | |
| CFO & Treasurer | 1.8yrs | US$54.50k | no data | |
| C.T.O. | no data | no data | no data |
1.8yrs
Average Tenure
48yo
Average Age
Experienced Management: RVRC's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 5.3yrs | US$5.01m | 4.61% $ 1.4m | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 4.1yrs | US$10.00k | no data | |
| Independent Director | 4.1yrs | US$10.00k | 0% $ 0 | |
| Chairman | 1.8yrs | US$239.00k | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data |
4.1yrs
Average Tenure
54yo
Average Age
Experienced Board: RVRC's board of directors are considered experienced (4.1 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/12 19:34 |
| End of Day Share Price | 2025/01/31 00:00 |
| Earnings | 2023/12/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Revium Rx is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.